These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22902051)

  • 1. Spliceosome-related gene mutations in myelodysplastic syndrome can be used as stable markers for monitoring minimal residual disease during follow-up.
    Matsuda K; Ishida F; Ito T; Nakazawa H; Miura S; Taira C; Sueki A; Kobayashi Y; Honda T
    Leuk Res; 2012 Nov; 36(11):1393-7. PubMed ID: 22902051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of allele-specific quantitative PCR using genomic DNA to monitor minimal residual disease based on mutant gene levels following allogeneic hematopoietic stem cell transplantation in patients with hematological malignancies: comparison of mutant levels with autologous DNA percentage by short tandem repeat-PCR.
    Taira C; Matsuda K; Saito S; Sakashita K; Sugano M; Okumura N; Honda T
    Clin Chim Acta; 2012 Feb; 413(3-4):516-9. PubMed ID: 22138486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
    Aslan D; Garde C; Nygaard MK; Helbo AS; Dimopoulos K; Hansen JW; Severinsen MT; Treppendahl MB; Sjø LD; Grønbæk K; Kristensen LS
    Oncotarget; 2016 Mar; 7(9):9951-63. PubMed ID: 26848861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
    Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
    Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
    Janusz K; Del Rey M; Abáigar M; Collado R; Ivars D; Hernández-Sánchez M; Valiente A; Robledo C; Benito R; Díez-Campelo M; Ramos F; Kohlmann A; Cañizo CD; Hernández-Rivas JM
    Leuk Res; 2017 May; 56():82-87. PubMed ID: 28222336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
    Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
    Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome.
    Chen CY; Lin LI; Tang JL; Ko BS; Tsay W; Chou WC; Yao M; Wu SJ; Tseng MH; Tien HF
    Br J Haematol; 2007 Nov; 139(3):405-14. PubMed ID: 17910630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome.
    Nagehan P; Sabbir M; Song J; Mohammad H
    J Clin Exp Hematop; 2023; 63(3):173-176. PubMed ID: 37766563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome.
    Cilloni D; Saglio G
    Acta Haematol; 2004; 112(1-2):79-84. PubMed ID: 15179007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.
    Damm F; Nguyen-Khac F; Fontenay M; Bernard OA
    Leukemia; 2012 Sep; 26(9):2027-31. PubMed ID: 22484420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCR for monitoring of minimal residual disease in hematologic malignancy.
    Matsuda K; Sugano M; Honda T
    Clin Chim Acta; 2012 Jan; 413(1-2):74-80. PubMed ID: 22057038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
    Boultwood J; Dolatshad H; Varanasi SS; Yip BH; Pellagatti A
    Adv Biol Regul; 2014 Jan; 54():153-61. PubMed ID: 24080589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of minimal residual disease using allele (mutation) -specific PCR].
    Matsuda K
    Rinsho Byori; 2014 Jun; 62(6):552-9. PubMed ID: 25151774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.
    Shirai CL; White BS; Tripathi M; Tapia R; Ley JN; Ndonwi M; Kim S; Shao J; Carver A; Saez B; Fulton RS; Fronick C; O'Laughlin M; Lagisetti C; Webb TR; Graubert TA; Walter MJ
    Nat Commun; 2017 Jan; 8():14060. PubMed ID: 28067246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 mutation in advanced stage of primary myelodysplastic syndrome.
    Tang JL; Tien HF; Lin MT; Chen PJ; Chen YC
    Anticancer Res; 1998; 18(5B):3757-61. PubMed ID: 9854490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of TP53 and FMS gene mutations in children with myelodysplastic syndrome.
    Jekic B; Novakovic I; Lukovic L; Kuzmanovic M; Popovic B; Milasin J; Bunjevacki G; Damnjanovic T; Cvjeticanin S; Bunjevacki V
    Cancer Genet Cytogenet; 2006 Apr; 166(2):163-5. PubMed ID: 16631474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
    Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
    Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling human RNA spliceosome mutations in the mouse: not all mice were created equal.
    Xu JJ; Smeets MF; Tan SY; Wall M; Purton LE; Walkley CR
    Exp Hematol; 2019 Feb; 70():10-23. PubMed ID: 30408513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.
    Wulfert M; Küpper AC; Tapprich C; Bottomley SS; Bowen D; Germing U; Haas R; Gattermann N
    Exp Hematol; 2008 May; 36(5):577-86. PubMed ID: 18439489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.